| Literature DB >> 30627177 |
Soheila Khalilzadeh1, Maryam Hassanzad1, Mihan PourAbdollah Toutkaboni1, Sabereh Tashayoie Nejad1, Fatemeh-Maryam Sheikholeslami1, Ali Akbar Velayati1.
Abstract
BACKGROUND: Cystic Fibrosis (CF) is a life-threatening recessive genetic disorder resulting from mutations in the gene encoding the fibrosis transmembrane conductance regulator protein (CFTR). The CF clinical phenotype shows wide variation ranging from severe disease in early childhood in those homozygous for the p.Phe508del mutation to absence of the vas deferens in otherwise healthy men homozygous for the p.Arg117His mutation.Entities:
Keywords: Cystic Fibrosis; Gene; Genotype; Iran; Mutation; Patients; Phenotype
Year: 2018 PMID: 30627177 PMCID: PMC6320558
Source DB: PubMed Journal: Tanaffos ISSN: 1735-0344
Demographic data of CF patients registered in Pediatric Respiratory Research Center of Iran
| Mean | 6.652±15.56 years | ||
| Median | 16 years | ||
| Range | 2 to 33 years | ||
| 0–14 | 24 (38.7%) | ||
| 15–20 | 36 (58.1%) | ||
| 30 and over | 2 (3.2%) | ||
| Male | 35 (56.45%) | ||
| Female | 27 (43.54%) | ||
| Iranian patients | 60 (96.77%) | ||
| Non-Iranian patients | Afghan | 1 (1.6%) | |
| Arab | 1 (1.6%) | ||
| Mean | 93.415±66.15 months | ||
| Median | 10 months | ||
| <5th percentile | 33 (53.2%) | ||
| Normal | 26 (42%) | ||
| Undetermined | 3 (5%) | ||
| >60meq/l | 41 (66%) | ||
| =60meq/l | 2 (3%) | ||
| undetermined | 19 (31%) | ||
| 46 (74.2%) | |||
| Bronchiectasis | 56 (90.3%) | ||
| Pancreatic insufficiency | 35 (56.45%) | ||
| Liver complication | 6 (9.67%) | ||
| Nasal polyp | 3 (4.8%) | ||
| Diabetes mellitus | 8 (13%) | ||
| undetermined | |||
| 36 (58.1%) | |||
| 14 (22.6%) | |||
| 4 (6.45%) | |||
| 4 (6.45%) | |||
| 2 (3.22%) |
Spectrum of CFTR mutations detected in 124 alleles of the CF patients registered at Pediatric Respiratory Disease Research Center of Iran.
| 1 | C.1521_1523DelCTT | P.Phe508Del | EX10 | 42 | 33.9 |
| 2 | C.1519_1521DelATC | P.Ile507Del | EX10 | 5 | 4 |
| 2 | C.[350G>A;1210–12] | P.Arg117His;[5T] | EX4 | 7 | 5.7 |
| 3 | C.[350G>A;1210–12] | P. Arg117His;[7T] | E4 | 5 | 4 |
| 4 | C.3846G > A | P.Trp1282X | EX20 | 7 | 5.7 |
| 5 | C.1624G > T | P.Gly542X | EX11 | 5 | 4.0 |
| 6 | C.3909C > G | P.Asn1303Lys | EX21 | 3 | 2.4 |
| 7 | C.1652G > A | P.Gly551Asp | EX11 | 2 | 1.6 |
| 8 | C.489 + 1G > T | C621 + 1 G>T | IN4 | 2 | 1.6 |
| 9 | C.1585–1G > A | C1717–1 G>A | IN10 | 2 | 1.6 |
| 10 | C.1657C > T | P.Arg553X | EX11 | 0 | 0 |
| 11 | C.1678A>G | P.Arg560Thr | EX11 | 0 | 0 |
| 12 | U | 44 | 35.5 |
Figure 1.Geographic distribution of P.Phe508del mutation in the CF patients registered at Pediatric Respiratory Disease Research Center of Iran.
Figure 2.Relationship of p.Arg117His;[5T] mutation with insufficiency pancreatic in the CF patients registered at Pediatric Respiratory Disease Research Center of Iran.